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Introduction: Mesalazine remains the first line treatment for the induction and the maintenance
of remission in mild to moderate ulcerative colitis (UC). Its efficacy as a maintenance treatment
after a first flare treated with corticosteroids has not been specifically studied. The aims of our
work were to study a cohort of UC patients treated with mesalazine after a course of oral
systemic corticosteroids and to identify predictive factors of relapse and of colectomy.
Material and method: We studied retrospectively a cohort of 143 UC patients, who never
received immunosuppressive drugs, and treated for the first time with oral corticosteroids for a
flare. Among patients responding to corticosteroids, we studied the group treated by mesalazine
after the flare.
Results: Fifty% (n=52) achieved a complete clinical remission with steroid weaning. In this
group, 67% (n=35) received oral mesalazine. Seventy-five % of patients treated by mesalazine
relapsed (median 29months, range: 1–156). Fourteen % required a colectomy (median 11months,
range: 1–24). Kaplan Meier curve showed a relapse rate and a colectomy rate over one year of 26%
and 11% respectively. In multivariate analysis, male gender and short duration of disease were
predictive factors of the time-to-relapse. No factor was predictive of time-to-colectomy.
Conclusion: Maintenance efficacy of mesalazine over one year after a first course of
corticosteroids for a disease flare is reasonably high. The longer-term relapse rate becomes
higher in male patients with a short disease duration. An immunosuppressive treatment could be
discussed in case of further relapse despite improved medication-adherence. Medication-
adherence should first be assessed and promoted. An immunosuppressive treatment could be
discussed in case of further relapse despite improved medication-adherence.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.66 72 56; fax: +32 4 36678 89.
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2 C. Bello et al.1. Introduction scribed factors, using either a Chi2 or Kruskal–Wallis test, asUlcerative colitis (UC) is a chronic inflammatory disease
affecting the rectum and the colon to a variable extent. The
primary therapeutic goals in UC are: corticosteroid-free
remission, avoidance of surgery, and the prevention of
colorectal cancer. Treatment of UC depends on the
anatomical extent, severity, and chronicity of the disease,
as well as the development of complications.1,2 Mesalazine
still remains the first line treatment for induction and
maintenance of remission in mild to moderate UC.3–5
However, a large majority of patients will require oral
corticosteroid therapy for a relapse.6,7 While requiring
corticosteroid treatment for a flare in Crohn's diseases (CD)
it is now broadly considered as an indication for immuno-
suppressive drug or anti-TNF therapy,8,9 the need for
immunosuppressive treatment after a first successful steroid
course in UC is less well established. Efficacy of mesalazine
as a maintenance treatment after a first course of
corticosteroids has not been specifically studied. The
primary endpoint of our work was to study the evolution of
a cohort of UC patients treated with mesalazine after a first
course of corticosteroids. The secondary aim was to identify
predictive factors of relapse and of colectomy in these
patients.
2. Patients and methods
A total of 143 patients with a firm diagnosis of UC (according
to the criteria of Lennard-Jones)10 who required a first oral
systemic corticosteroid course, and who were regularly
followed at our institution, were screened for inclusion.
We retrospectively studied the group of patients responding
to steroids, but without steroid-dependence, who were
subsequently treated with mesalazine after the flare. For all
these patients we recorded: age at diagnosis; disease
duration at the flare; smoking habit; location of the disease
at diagnosis and at relapse according to the Montreal
classification11; and haemoglobin, platelet count and c-
reactive protein (CRP). Patients were defined as smokers if
they smoked at least seven cigarettes/week and non-
smokers if they had never smoked or had stopped smoking
before diagnosis. The flare was assessed retrospectively
based on patient medical notes. A flare was considered to
have occurred when the physician in charge of the patient
documented it in the notes and changed the treatment
accordingly. These flares were characterised by a combina-
tion of symptoms, including diarrhoea, abdominal pain,
blood loss, fever, weight loss, and worsening of the general
physical condition. Satisfactory clinical response was defined
as a resolution of clinical symptoms. Steroid-dependence
was defined as a recurrence of clinical symptoms during the
steroidweaning orwithin the 3 months after steroid cessation.
Mesalazinewas taken at aminimumdose of 2.4 grams per day.
Exclusion criteria were the previous use of systemic steroids or
immunosuppressive drugs, or a severe flare requiring intrave-
nous corticosteroids. Results are expressed in median (range).
A Cox regression and a Kaplan Meier curve were used to study
the time-to-relapse and the time-to-colectomy. We initially
used univariate analysis to study the association between
time-to-relapse or time-to-colectomy and each of the de-Please cite this article as: Bello C, et al, Evolution and predictive facto
after a first course of corticosteroids, Journal of Crohn's and Colitis (required. A multivariate analysis was then performed using
stepwise discriminant analysis. This multivariate analysis was
performed on a subgroup of 26 patients for whom we had
complete data. Haemoglobin, platelet count and CRP were
excluded from the multivariate analysis due to an excess of
missing values. A p valueb0.05 was considered significant.
3. Results
3.1. Patients outcome
We identified 143 patients suffering from a mild to moderate
flare of UC requiring a first course of oral corticosteroid, in
whom 15% (n=21) did not respond to the treatment whereas
85% (n=122) achieved a satisfactory clinical response
(Fig. 1). Among these patients, 42% (n=51) developed a
steroid-dependence and 43% did not relapse after having
stopped treatment. Sixteen % (n=19) had no follow-up.
Looking at the subgroup in remission after full corticosteroids
weaning, we identified 35 patients (67%) receiving mesala-
zine as maintenance therapy. One year after the first flare,
13 of 35 patients on mesalazine as monotherapy were still in
remission. The median maximum follow-up was 118 months
(16–322). At the maximum follow-up, 26 patients had
relapsed, with a median delay of 39 months between the
withdrawal of the corticosteroids and the flare (Fig. 2). The
Kaplan Meier curve shows that about 50% of patients on
mesalazine are in remission after two years, but there is a
higher risk of relapse over longer follow-up. At 10 years,
approximately 80% have relapsed (Fig. 3). Regarding the risk
of colectomy, we identified 6 patients requiring a colectomy
within a median of 18 months (Fig. 2). The Kaplan Meier
curve showed a low risk of colectomy during the first years
following a flare (about 5% at 2 years), which finally reached
20% after 5 years (Fig. 4).
Demographic and clinical characteristics in this subgroup
are shown in Table 1. Disease location was stable over long-
term follow-up. According to the Montreal classification,
24%, 48% and 28% of patients were E1, E2 and E3 at diagnosis,
respectively. At the time of relapse, 80% of patients had no
extension of the disease. Among the 5 patients with a disease
extension, all of them had a pancolitis at the time of relapse,
while at the time of diagnosis, 3 of them had proctitis and 2
of them had a left-sided colitis.
3.2. Association between UC evolution and
demographic, clinical and biological characteristics
Demographic, clinical and biological characteristics of
relapsers and non-relapsers at 1 year, are shown in
Table 3. In univariate analysis, no demographic, clinical or
biological factors were predictive of a relapse at one year.
The univariate analysis of the same parameters for the
prediction of time-to-relapse over the total follow-up
(median=118 months) was unable to identify predictive
factors of time-to-relapse (Table 2). In multivariate analysis,
biological parameters were not selected because of a lack of
data in several patients. Two independent predictive factors
of time-to-relapse after a first course of oral corticosteroids
were identified. The male gender was a risk factor (p=0.03,rs of relapse in ulcerative colitis patients treated with mesalazine
2011), doi:10.1016/j.crohns.2010.12.011
Figure 1 Flowchart of a monocentre retrospective UC cohort after a first course of oral corticosteroids. 122 patients (85%)
responded. Among 52 patients with corticosteroids weaning, 35 were treated with mesalazine and finally included in our study. The
rates of steroid-resistance and steroid-dependence were 15% and 49% respectively.
3Position of 5ASA after a relapse in RCUHHR=4, CI 95%: 1.46–11.5), whereas long disease duration
was a protective factor of time-to relapse (p=0.03, HR 0.98,
CI 95%: 0.97–0.99). No clinical or demographic factors were
predictive of colectomy (Table 4).4. Discussion
To date, no trial has specifically demonstrated the ability to
maintain steroid-induced remission with mesalazine in UC
after a first steroid course. An oral course of corticosteroids
may be required in patients non-responding to oral mesala-Figure 2 Outcome of UC patients treated with mesalazine
after a first course of oral corticosteroids.
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after a first course of corticosteroids, Journal of Crohn's and Colitis (zine and/or rectal medication. Remission or partial response
can be achieved in 55 to 80% of the patients. In our cohort,
we obtained 85% complete clinical response after a first
course of oral corticosteroid. In the subgroup of patients who
could be withdrawn from steroids, the large majority (63%)
were still in remission with mesalazine as monotherapy oneFigure 3 Relapse-free Kaplan–Meier curve. The risk of relapse
is low over the first year but increases importantly over longer
follow-up.
rs of relapse in ulcerative colitis patients treated with mesalazine
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Figure 4 Colectomy-free Kaplan–Meier curve. The risk of
colectomy was very low during the first year after corticosteroid
treatment but reached about 20% after 10 years.
4 C. Bello et al.year after the flare. When compared to the natural history of
untreated UC following an initial flare, with a relapse rate of
73% over 1 year,12,13 our study suggests that mesalazine can
be considered as an effective drug for the maintenance of
corticosteroid-free remission. However the relapse rate over
the long term reaches more than 75%, suggesting that
mesalazine may eventually become insufficient in most of
these patients. These results must be qualified by the fact
that our retrospective study may have focused on a subgroup
of more severe patients. Coming from a large cohort of 143
patients, we were able to analyze only a subgroup of 35
patients. This was in part because of the high rate of steroid-
dependence in our cohort, with a rate of 42% compared with
an expected rate of about 20% at one year.14 Although high
rates of steroid-dependence have already been described in
the literature in CD patients (45%)15 and in UC paediatric
population (45%),16 such high rates have been less well
reported in adult UC populations, with the highest at about
30%.7 As this study was performed in a tertiary referral
centre, our cohort may reflect a more severe UC population,
and this could in partly explain why the results differ from
those observed in population-based studies. Secondly, manyTable 1
Patients' features





Disease location at diagnosis (Montreal)
Disease location at relapse (Montreal)
CRP at relapse (mg/L)
Hb at relapse (g/dL)
Platelets at relapse (10³/mm³)
* Median (range).
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after a first course of corticosteroids, Journal of Crohn's and Colitis (patients (16%) were lost to follow-up, and it is possible that
the majority of these had mild UC, well controlled under
monotherapy or topical treatment, and who therefore did
not return for hospital follow-up. This would have introduced
a bias to more severe disease in the study population.
In UC, 50% of patients will eventually require mainte-
nance therapy with immunosuppressive drugs, but the
optimal timing to introduce them has not been extensively
studied.17 This is different in Crohn's disease where marginal
efficacy of mesalazine and high frequency of complications
and finally surgery has led to the search for predictive factors
of poor outcome.18,19 Among those, the need for steroids to
treat the first flare of the disease has been repeatedly shown
to be an independent predictor of the development of a
disabling disease over the short term. Hence the need for
such steroid treatment has become broadly considered as an
indication for immunosuppressive and/or anti-TNF treat-
ment to maintain disease remission. Our data indicates that
this should not be extrapolated to ulcerative colitis.
The second aim of our work was to identify factors
predictive of clinical relapse or colectomy in these patients.
By identifying such factors, patients at high risk of relapse
after a first course of corticosteroids may be offered
treatment other than 5ASA to prevent future flares. As
previously mentioned, only a small number of patients could
be included in the univariate and multivariate analyses.
Therefore, the results must be interpreted with caution. The
multivariate analysis suggests that long disease duration was
associated with a lower risk of relapse. These data have
already been shown by one previous study. Langholz et al.12
demonstrated that the risk of relapse became lower over
time, while the risk of complications including colorectal
cancer became higher in the presence of extensive disease.
The probability of long-term relapse was higher in male
patients in our cohort. There is no clear evidence in the
literature that gender may influence the disease course,
however non-adherence to medical therapy has been
reported to be associated with a high rate of relapse and
complication in UC.20 Kane et al. showed prospectively that
among UC patients with a 12 month-recurrence, 68% were
non-adherent to 5ASA.20 The overall non-adherence rate in
Europe was about 29% where non-adherence was defined as
taking less than 80% of prescribed medication.21 Many
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Table 2 Univariate analysis of predictive factors for maximum follow-up relapse. * Median (range).
Relapse 0 Relapse + OR P Value
Age at diagnosis (months)* 25 (14–45) 29 (10–76) 2.3 0.12
Sex (n): F 6 (66.7%) 10 (38.5%) 2.04 0.15
M 3 (33.3%) 16 (61.5%)
Disease duration (months)* 36 (0–264) 10.5 (0–168) 2.8 0.09
Tobacco (n): + 0 (0%) 21 (84%) 0.0018 0.96
0 8 (100%) 4 (16%)
Familial history (n): + 0 (0%) 4 (26.7%) 0.0022 0.96
0 6 (100%) 11 (73.3%)
Montreal at diagnosis (n): E1 2 (25%) 4 (20%) 1.3 0.52
E2 5 (62.5%) 9 (45%)
E3 1 (12.5%) 7 (35%)
Platelets (×l000/mm3)* 380 (368–498) 447 (327–485) 0.66 0.46
Hb (g%)* 12.4 (8.6–12.7) 11.2 (8–14.6) 0.0003 0.98
CRP(mg/l)* 16.6 (6.6–47.7) 99.4 (2.5–122.4) 1.7 0.19
5Position of 5ASA after a relapse in RCUHand the male gender. Lack of adherence linked to male
gender could explain the higher risk of time-to-relapse of this
subgroup in our study. Moreover, a recent diagnosis and
disease duration shorter than 5 years were also associated
with significantly worse adherence (24% of patients).23 This
suggests that poor adherence could also contribute to higher
risk of relapse in the subgroup with shorter disease duration
in our study. Despite the fact that adherence to medical
therapy could not be assessed in the present retrospective
study, these associations should support a good physician–
patient relationship that achieves higher medication-
adherent rates. Multiple studies have shown that smoking
is a protective factor in UC, while ex or non-smokers have a
higher risk of relapsing disease.24 Our cohort, with only 4
active smokers, was too small to evaluate the effect of
smoking. In UC, disease extension over time does occur.
Pancolitis is observed at diagnosis in about 1/3 of patients,
but observed in another third of patients 20 years after the
diagnosis. Extensive disease is associated with a higher rate
of complication.25,26 In our study, disease extent was stable
over time in 80% of patients and was not associated with
time-to-relapse or colectomy. No other clinical or demo-Table 3 Univariate analysis of predictive factors for one-year re
Relapse 0
Age at diagnosis (months)* 26 (10–66)
Sex (n): F 12 (54.6%)
M 10 (45.4%)
Disease duration (months)* 31.5 (0–264)
Tobacco (n): + 1 (5%)
0 19 (95%)







Platelets (×l000/mm3)* 428 (368–498)
Hb (g%)* 10.5 (8–14.6)
CRP (mg/I)* 43.8 (3.6–122.4)
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after a first course of corticosteroids, Journal of Crohn's and Colitis (graphic factor was predictive of colectomy. This could be
explained by the low absolute number of colectomies in our
cohort despite the fact that the proportion of colectomy
(17%) was within the range of previous studies. The risk of
colectomy can reach 20 to 30% after 25 years of disease
duration but some series also report lower rates. Hoie et
al.25,26 reported a 10-year cumulative risk of colectomy of
8.7%, which was associated with extensive colitis and
geographic variations.
Our study has some limitations. First, it is retrospective.
As previously discussed, we finally studied a rather small
group of 35. Data coming from the Kaplan Meier curves can't
be interpreted beyond 10 years because of the small number
of remaining patients. The subgroups of smokers and patients
undergoing colectomy were small which could explain why
the statistical analysis was not significant in these patients.
As expected in retrospective studies some data, such as CRP
which has been associated with poor outcome in UC,27,28
were missing and couldn't be included in the multivariable
analysis. Likewise, mucosal healing, which has been associ-
ated with longer time-to-relapse29 could not be assessed due
to the lack of data on follow-up colonoscopies.laspe. * Median (range).
Relapse + OR P Value
30 (14–76) 1.09 0.29
4 (30.8%) 1.8 0.17
9 (69.2%)
6 (0–55) 2.3 0.12
3 (23%) 2.04 0.15
10 (77%)
2 (9.5%) 0.59 0.44
5 (71.5%)
2 (18.2%) 0.17 0.91
6 (54.6%)
3 (27.3%)
387 (327–447) 0.75 0.39
12.6 (11.2–13–9) 0.71 0.4
60 (2.5–99.4) 0.04 0.84
rs of relapse in ulcerative colitis patients treated with mesalazine
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Table 4 Univariate analysis of predictive factors for maximum follow-up colectomy. * Median (range).
Colectomy 0 Colectomy + OR P Value
Age at diagnosis (months)* 29 (14–76) 22.5 (10–49) 1.6 0.21
Sex (n): F 14 (48.3%) 2 (33.3%) 0.43 0.5
M 15 (51.7%) 4 (66.7%)
Disease duration (months)* 19 (0–264) 34 (0–60) 0.24 0.62
Tobacco (n): + 2 (7.4%) 2 (33.3%) 2.6 0.1
0 25 (92.6%) 4 (66.7%)
Familial history (n): + 3 (16.7%) 1 (33.3%) 0.44 0.51
0 15 (83.3%) 2 (66.7%)
Montreal at diagnosis (n): E1 5 (20.8%) 1 (25%)
E2 12 (50%) 2 (50%)
E3 7 (29.2%) 1 (25%)
Platelets (×l000/mm3)* 447 (327–498) 384 0.38 0.54
Hb (g%)* 11.2 (8–13.9) 14.6 0.31 0.58
CRP (mg/I)* 39.9 (2.5–122.4) 122.4 0.0064 0.93
6 C. Bello et al.5. Conclusions
Only 1 in 3 patients treated with mesalazine after a first flare
requiring oral corticosteroids relapsed over 1 year. However,
over longer follow-up, three quarters of patients finally
relapsed and 1 in 6 underwent colectomy. Mesalazine can
thus be considered as an effective maintenance therapy over
one year after a first flare treated with systemic steroids.
Nevertheless, the relapse rate over longer follow-up
becomes much higher particularly in male patients with
short disease duration. As poor adherence to medication
(leading to relapses and complications) has particularly been
described in those categories of patients, adherence should
first be assessed and promoted by effective patient–
physician dialogue. Immunosuppressive treatment could
then be discussed in the case of further relapse.References
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